Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Focus of the Report: This health technology assessment focuses on the use of genicular nerve blocks (GNB) for the management of knee pain associated with osteoarthritis of the knee (KOA) or persistent pain following total knee arthroplasty (TKA).
Technology Description: In a GNB proced…
Focus of the Report: This report focuses on electronic monitoring (EM) of hand hygiene (HH) in a hospital setting.
Technology Description: Electronic HH monitoring systems vary in their degree of sophistication. The simplest are straightforward counters that record the number of times …
Focus of the Report: This report focuses on magnetic resonance elastography (MRE) for diagnosis and staging of liver fibrosis.
Technology Description: MRE relies on visualization of the passage of sound waves through liver tissue while the patient is in a magnetic resonance imaging (MR…
This report evaluates the analytical validity, clinical validity, and clinical utility of the DecisionDx-UM test.
Chloroquine (and its metabolite, hydroxychloroquine) is an oral 4-aminoquinoline antimalarial agent that has demonstrated antiviral effects on SARS-CoV and SARS-CoV-2 in vitro. It is being evaluated for the treatment of COVID-19.
This report evaluates the clinical utility of prenatal whole genome sequencing and prenatal whole exome sequencing to improve diagnosis and inform pregnancy and post-pregnancy patient management where fetal abnormalities have been detected by ultrasound or other testing.
Inebilizumab is an anti-CD19 monoclonal antibody. It was developed in response to the unmet treatment needs of patients with neuromyelitis optica spectrum disorder (NMOSD), a rare and debilitating autoimmune demyelinating disease that primary affects the optic nerves and spinal cord. Inebilizumab is administered every 6 months by intravenous infusion.
Focus of the Report: This report focuses on the use of lymphovenous anastomosis (LVA) for the surgical treatment of patients with lymphedema.
Technology Description: LVA is a microsurgical procedure used to restore adequate lymphatic drainage from tissues of the upper or lower extremit…
Focus of the Report: This health technology assessment focuses on prostatic urethral lift (PUL) with the UroLift System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Technology Description: The UroLift System is a minimally invasi…
Remdesivir is an investigational, intravenously administered antiviral agent proposed for treatment of COVID-19.